Resumen de An analysis of basal insulin added to dual oral therapy in type 2 diabetes patients

S. S. Alavudeen, C. K. Dhanapal, K. M. Alakhali, W. Venkatachalam, Noohu Abdulla Khan

• Introduction: In patients with type 2 diabetes, achieving and maintaining the glycemic control over time will generally require multiple therapies, including insulin. The most convenient and simple ways to initiate insulin treatment in patients with type 2 diabetes are most probably the use of long-acting basal insulin at bedtime or injection of premixed insulin before one or more meals.

  Objective: To evaluate the efficacy and safety of basal insulin added to the previous dual oral therapy among the type 2 diabetes patients who failed to achieve glycemic control with two oral agents’ regimen (OHA).

  Method: Single-centre, observational study evaluate the efficacy and safety of the regimen of basal insulin added to the previous dual oral therapy among patients with type 2 diabetes whose glycemic targets were not achieved with the use of oral hypoglycemic agents. A total of 73 subjects were eligible for this study. At study end, the mean HbA1c value was reduced from 10.7 ±1.5% to 8.5 ±1.4% (P <0.0001). FBG was decreased from 209.8 ±50.3 mg/dl to 141 ±45.3 mg/dl. One quarter of the patients achieved the target HbA1c level and FBG level. Only 16.4% of patients had confirmed hypoglycemic.

  Conclusion: The basal insulin added with previous dual OHA regimen is more acceptable and leads to improvements in HbA1c and thereby a reduction in the long-term complications of diabetes